{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-25-000087","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.996239+00:00","generated_at":"2026-05-22T12:02:32.555148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs","bullets":["Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.","Net income $6.6M ($0.14 diluted EPS) vs $0.5M ($0.01) a year ago; adjusted net income $12.0M ($0.26 adjusted EPS).","SNS segment net sales $101.1M with 8.7% volume growth driven by enteral feeding and neonate solutions.","PM&R segment net sales $56.2M; RFA product sales grew 8.2% from ESENTEC/TRIDENT momentum.","2025 revenue guidance reaffirmed at $665-$685M; adjusted EPS guidance lowered to $0.75-$0.95 due to tariff impacts."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-25-000087","json":"https://secwatch.observer/filing/0001606498-25-000087.json","markdown":"https://secwatch.observer/filing/0001606498-25-000087.md","text":"https://secwatch.observer/filing/0001606498-25-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649825000087/0001606498-25-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649825000087/avns-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:02:32.555148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}